Abstract:The purpose of this study was to develop a novel therapy for Parkinson's disease (PD). We recently reported that dextromethorphan (DM), an active ingredient in a variety of widely used anticough remedies, protected dopaminergic neurons in rat primary mesencephalic neuron-glia cultures against lipopolysaccharide (LPS)-mediated degeneration and provided potent protection for dopaminergic neurons in a MPTP mouse model. The underlying mechanism for the protective effect of DM was attributed to its anti-inflammatory activity through inhibition of microglia activation. In an effort to develop more potent compounds for the treatment of PD, we have screened a series of analogs of DM, and 3-hydroxymorphinan (3-HM) emerged as a promising candidate for this purpose. Our study using primary mesencephalic neuron-glia cultures showed that 3-HM provided more potent neuroprotection against LPS-induced dopaminergic neurotoxicity than its parent compound. The higher potency of 3-HM was attributed to its neurotrophic effect in addition to the anti-inflammatory effect shared by both DM and 3-HM. First, we showed that 3-HM exerted potent neuroprotective and neurotrophic effects on dopaminergic neurons in rat primary mesencephalic neuron-glia cultures treated with LPS. The neurotrophic effect of 3-HM was glia-dependent since 3-HM failed to show any protective effect in the neuron-enriched cultures. We subsequently demonstrated that it was the astroglia, not the microglia, that contributed to the neurotrophic effect of 3-HM. This conclusion was based on the reconstitution studies, in which we added different percentages of microglia ( 10 - 20%) or astroglia ( 40 - 50%) back to the neuron-enriched cultures and found that 3-HM was neurotrophic after the addition of astroglia, but not microglia. Furthermore, 3-HM-treated astroglia-derived conditioned media exerted a significant neurotrophic effect on dopaminergic neurons. It appeared likely that 3-HM caused the release of neurotrophic factor(s) from astroglia, which in turn was responsible for the neurotrophic effect. Second, the anti-inflammatory mechanism was also important for the neuroprotective activity of 3-HM because the more microglia were added back to the neuron-enriched cultures, the more significant neuroprotective effect was observed. The anti-inflammatory mechanism of 3-HM was attributed to its inhibition of LPS-induced production of an array of pro-inflammatory and neurotoxic factors, including nitric oxide (NO), tumor necrosis factor alpha (TNF-alpha), prostaglandin E-2 (PGE(2)) and reactive oxygen species (ROS). In conclusion, this study showed that 3-HM exerted potent neuroprotection by acting on two different targets: a neurotrophic effect mediated by astroglia and an anti-inflammatory effect mediated by the inhibition of microglial activation. 3-HM thus possesses these two important features necessary for an effective neuroprotective agent. In view of the well-documented very low toxicity of DM and its analogs, this report may provide an important new direction for the development of therapeutic interventions for inflammation-related diseases such as PD.

Neuroprotective Effect of Dextromethorphan in the MPTP Parkinson's Disease Model: Role of NADPH Oxidase

MPTP-Induced Impairment of Cardiovascular Function

Reduced Nicotinamide Adenine Dinucleotide Phosphate Inhibits MPTP-Induced Neuroinflammation and Neurotoxicity

Dextromethorphan Protects Dopaminergic Neurons Against Inflammation-Mediated Degeneration Through Inhibition of Microglial Activation

NADPH Ameliorates MPTP-induced Dopaminergic Neurodegeneration Through Inhibiting P38mapk Activation

Neuroprotective effects of 2,4-dinitrophenol in an acute model of Parkinson’s disease

[Protective Effect of Nicotinamide in a Mouse Parkinson's Disease Model].

Neuroprotective Effects of Tetramethylpyrazine Against Dopaminergic Neuron Injury in a Rat Model of Parkinson's Disease Induced by MPTP.

Dexmedetomidine protects against degeneration of dopaminergic neurons and improves motor activity in Parkinson's disease mice model

Orally Administered Neohesperidin Attenuates MPTP-Induced Neurodegeneration by Inhibiting Inflammatory Responses and Regulating Intestinal Flora in Mice

Demethylenetetrahydroberberine protects dopaminergic neurons in a mouse model of Parkinson's disease

Neuroprotective Effects of Pramipexole Transdermal Patch in the MPTP-induced Mouse Model of Parkinson's Disease

3‐Hydroxymorphinan is Neurotrophic to Dopaminergic Neurons and is Also Neuroprotective Against LPS‐induced Neurotoxicity

Nicotine alleviates MPTP-induced nigrostriatal damage through modulation of JNK and ERK signaling pathways in the mice model of Parkinson's disease

Neuroprotective Effects of Stemazole in the Mptp-Induced Acute Model of Parkinson'S Disease: Involvement of the Dopamine System

Catalytic Metalloporphyrin Protects Against MPTP-induced Parkinson's Disease in Mice

Deferoxamine-mediated up-regulation of HIF-1α prevents dopaminergic neuronal death via the activation of MAPK family proteins in MPTP-treated mice.

Dimethyl Fumarate Exerts a Neuroprotective Effect by Enhancing Mitophagy via the NRF2/BNIP3/PINK1 Axis in the MPP+ Iodide-Induced Parkinson's Disease Mice Model

Therapeutic effects of multifunctional tetramethylpyrazine nitrone on models of Parkinson's disease in vitro and in vivo.

Neuroprotective Effect of Kaempferol Against A 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Mouse Model of Parkinson'S Disease

Neuroprotective Effects and Mechanisms of Action of Multifunctional Agents Targeting Free Radicals, Monoamine Oxidase B and Cholinesterase in Parkinson's Disease Model.